Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

506

$million

Invested

104

innovative

Projects

13

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2023

Annual Report

Accelerating the Global Response to Antimicrobial Resistance

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
Wellcome
NIAID
UK Government
Bill & Melinda Gates Foundation
The Public Health Agency of Canada
Novo Nordisk Foundation

Events

Events

02.25.25

 

9th AMR Conference

04.11.25

 

ESCMID Global 2025

10.19.25

 

IDWeek 2025

CARB-X News

  • 02.06.2025  |  CARB-X funds AstraDx to develop rapid diagnostic to detect neonatal sepsis full release

  • 01.28.2025  |  CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia full release

  • 01.23.2025  |  CARB-X funds Immunartes to develop Staphylococcus aureus preventative full release

See All News

In The News

  • 01.30.2025  |  Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year full story

  • 01.27.2025  |  Health experts, academics, business leaders and local students will take centre stage at antimicrobial resistance conference as BioInfect returns to Liverpool full story

  • 01.24.2025  |  Muschel (Hera): “In Ue 35mila morti all’anno dovuti all’Amr, la ricerca priorità assoluta” full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.

Subscribe

* indicates required